UCB

News

UCB chases after Argenx with FcRN drug for myasthenia gravis

UCB has the positive result it was hoping for in its phase 3 trial of anti-neonatal FC receptor (FcRn) antibody rozanolixizumab for autoimmune disease generalised myasthenia gravis (gMG), s

News

Novartis takes aim at risky Parkinson's target with $1.5bn U...

Novartis has licensed a potential drug for Parkinson's from Belgium's UCB that it thinks could be the first oral, disease-modifying drug for the disease – if it can avoid the fate of earlie

News

Pharma group will develop 'digital endpoint' for atopic derm...

The development of digital medicine requires valid endpoints that can be used in clinical trials, and a consortium of pharma companies has just identified a new one for atopic dermatitis.

News

UCB licenses AI tech for spinal fracture detection to ImageB...

An artificial intelligence-based tool for identifying hard-to-detect spinal fractures, developed by Belgian drugmaker UCB, has been licensed out to ImageBiopsy Lab for further development.<

News

IL-17 tailender UCB gets EU OK for bimekizumab in psoriasis

UCB has been bringing up the rear in the IL-17 inhibitor category with bimekizumab, but now has EU approval for the drug and thinks it can mount a stiff challenge to the leaders, including

News